<DOC>
	<DOCNO>NCT01071239</DOCNO>
	<brief_summary>The trial propose single arm phase II treatment protocol design examine engraftment , toxicity , graft-versus-host disease , ultimate disease-free survival follow novel cytoreductive regimen include busulfan , cyclophosphamide fludarabine anti-thymocyte globulin ( ATG- non-chemotherapy drug whose role kill immune system ) treatment patient Fanconi anemia severe aplastic anemia ( SAA ) , myelodysplastic syndrome ( MDS ) acute myelogenous leukemia ( AML ) , lack HLA-genotypically identical donor use stem cell transplant derive ( 1 ) HLA-compatible unrelated donor ( 2 ) HLA haplotype-mismatched related donor .</brief_summary>
	<brief_title>Hematopoietic Stem Cell Transplant Fanconi Anemia</brief_title>
	<detailed_description>We currently recruit patient .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Fanconi Anemia</mesh_term>
	<mesh_term>Fanconi Syndrome</mesh_term>
	<criteria>Fanconi Anemia ( confirm mitomycin C DEB chromosomal breakage test one follow hematological diagnosis : Severe Aplastic Anemia , Myelodysplastic Syndrome , Acute Myelogenous Leukemia Karnofsky Lansy performance scale &gt; = 70 % . Must adequate cardiac , hepatic , renal pulmonary function . Must 7/8 8/8 available unrelated donor . Pregnant breastfeeding . Active CNS leukemic involvement Active uncontrolled viral , bacterial fungal infection Positive HIV .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Fanconi Anemia</keyword>
	<keyword>Hematopoietic stem cell transplant</keyword>
</DOC>